aceclidine/brimonidine (LNZ101) / LENZ Therap, CORXEL - LARVOL DELTA

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia (clinicaltrials.gov) - P3 | N=300 | Completed | Sponsor: Corxel Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Ophthalmology

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia (clinicaltrials.gov) - P3 | N=300 | Active, not recruiting | Sponsor: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Ophthalmology

Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia (clinicaltrials.gov) - P1 | N=21 | Completed | Sponsor: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Apr 2024 | Trial primary completion date: Jul 2024 ➔ Apr 2024

Trial completion • Trial completion date • Trial primary completion date • Ophthalmology

Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology

Phase 3 Safety Study for the Treatment of Presbyopia Subjects (clinicaltrials.gov) - P3 | N=361 | Completed | Sponsor: LENZ Therapeutics, Inc | Active, not recruiting ➔ Completed

Trial completion • Ophthalmology

Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects With Presbyopia (clinicaltrials.gov) - P1 | N=21 | Not yet recruiting | Sponsor: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.

New P1 trial • Ophthalmology

CLARITY: Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia (clinicaltrials.gov) - P3 | N=229 | Completed | Sponsor: LENZ Therapeutics, Inc | Active, not recruiting ➔ Completed

Trial completion • Ophthalmology

CLARITY: Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia (clinicaltrials.gov) - P3 | N=469 | Completed | Sponsor: LENZ Therapeutics, Inc | Active, not recruiting ➔ Completed

Trial completion • Ophthalmology

CLARITY: Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia (clinicaltrials.gov) - P3 | N=229 | Active, not recruiting | Sponsor: LENZ Therapeutics, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Ophthalmology

CLARITY: Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia (clinicaltrials.gov) - P3 | N=469 | Active, not recruiting | Sponsor: LENZ Therapeutics, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Ophthalmology

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: LENZ Therapeutics, Inc | Recruiting ➔ Completed

Trial completion • Ophthalmology

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia (clinicaltrials.gov) - P3 | N=300 | Not yet recruiting | Sponsor: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.

New P3 trial • Ophthalmology

Phase 3 Safety Study for the Treatment of Presbyopia Subjects (clinicaltrials.gov) - P3 | N=300 | Active, not recruiting | Sponsor: LENZ Therapeutics, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Ophthalmology

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: LENZ Therapeutics, Inc

New P1 trial • Ophthalmology

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: LENZ Therapeutics, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology

CLARITY: Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia (clinicaltrials.gov) - P3 | N=222 | Recruiting | Sponsor: LENZ Therapeutics, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology

Phase 3 Safety Study for the Treatment of Presbyopia Subjects (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: LENZ Therapeutics, Inc

New P3 trial • Ophthalmology

CLARITY: Phase 3 Efficacy Study in the Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia (clinicaltrials.gov) - P3 | N=222 | Not yet recruiting | Sponsor: LENZ Therapeutics, Inc

New P3 trial • Ophthalmology

Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia (clinicaltrials.gov) - P2 | N=58 | Completed | Sponsor: Alisyn Facemire | Recruiting ➔ Completed

Trial completion • Ophthalmology

CLARITY: Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia (clinicaltrials.gov) - P3 | N=435 | Recruiting | Sponsor: LENZ Therapeutics, Inc

New P3 trial • Ophthalmology

Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia (clinicaltrials.gov) - P2 | N=62 | Completed | Sponsor: LENZ Therapeutics, Inc | Active, not recruiting ➔ Completed

Trial completion • Ophthalmology

Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia (clinicaltrials.gov) - P2 | N=61 | Active, not recruiting | Sponsor: LENZ Therapeutics, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Ophthalmology